Gerald Brown, MD
Internal Medicine · Littleton, CONPI 1528029253
Payments from drug & device makers
Across 382 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$785
- Pfizer$772
- Johnson & Johnson$738
- Amgen$634
- AstraZeneca$446
- Novo Nordisk$349
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,140100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 39 | $785 |
| Pfizer | 70 | $772 |
| Johnson & Johnson | 45 | $738 |
| Amgen(2 entities) | 36 | $634 |
| AstraZeneca | 27 | $446 |
| Novo Nordisk | 21 | $349 |
| GSK | 18 | $324 |
| Lilly USA, LLC | 27 | $244 |
| Merck | 13 | $217 |
| Novartis | 11 | $200 |
| Amarin Pharma, Inc. | 5 | $184 |
| Sanofi-aventis U.S. LLC | 11 | $176 |
| Astellas Pharma US Inc | 7 | $128 |
| Boehringer Ingelheim | 7 | $119 |
| Bayer | 5 | $105 |
| Kowa Pharmaceuticals America, Inc. | 6 | $103 |
| Eisai Inc. | 5 | $85 |
| IBSA Pharma Inc. | 5 | $84 |
| Sanofi Pasteur Inc. | 3 | $67 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $52 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$122
How this compares
$6,140 in reported general payments places this provider in the 90th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 158 | $220,227 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $61,454 |
| MounjaroTirzepatide | 39 | $50,128 |
| OzempicSemaglutide | 29 | $45,950 |
| XareltoRivaroxaban | 34 | $43,825 |
| JardianceEmpagliflozin | 21 | $37,237 |
| FarxigaDapagliflozin Propanediol | 41 | $32,912 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $29,838 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $16,910 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $6,611 |
| Atorvastatin Calcium | 702 | $6,106 |
| SynthroidLevothyroxine Sodium | 53 | $5,687 |
| Nebivolol Hcl | 67 | $5,426 |
| Omeprazole | 148 | $3,840 |
| Levothyroxine Sodium | 312 | $3,317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $772 | $220,227158 claims |
| GSKTrelegy Ellipta | $324 | $61,45452 claims |
| Lilly USA, LLCMounjaro | $244 | $50,12839 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $446 | $49,82253 claims |
| Novo NordiskOzempic | $349 | $45,95029 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $119 | $43,84834 claims |
| Johnson & JohnsonXarelto | $738 | $43,82534 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $176 | $29,83823 claims |
| AbbVieSynthroid | $785 | $5,68753 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Littleton
- Andy FineLittleton$157K
- Sophia AmbrusoLittleton$62K
- Celinde StrohlLittleton$14K
- David ConwayLittleton$12K
- Pierre MalekLittleton$9K
- George FrankLittleton$9K
- Stanton ElziWheat Ridge$9.2M
- Jason HenryDenver$7.3M
- Kenneth CohenLakewood$4.5M
- Luke WebbColorado Springs$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.